METHOD FOR SELECTING THE TYPE OF IMMUNOMODULATION THERAPY AND DETERMINING DISEASE OUTCOME ON THE BASIS OF PATIENT INTERFERON STATUS ANALYSIS Russian patent published in 2000 - IPC

FIELD: medicine. SUBSTANCE: method involves determining general serum interferon activity, α/β interferon and j-interferon production by leukocytes in vitro. The determination procedure is carried out in whole blood samples incubated in RPMI-1640 medium in the presence of standard interferon synthesis inductors by titering the samples under test on the cell culture with following incubation with vesicular stomatitis virus. Reinoculated cultures sensitive to interferon action are used. After being incubated with virus, the cells are stained with crystal violet solution. The bound dye is dissolved and its quantity, being proportional to interferon activity, is measured using photometric method at 570-590 nm wavelength. General serum interferon activity being equal to 0-10 MU /ml, α/β interferon activity being equal to 250-520 MU, gamma-interferon activity interferon activity being equal to 110-250 MU, the testee is considered to be healthy person. General serum interferon activity being equal to 25-35 MU/ml, α/β interferon activity being equal to 60-110 MU/ml, gamma-interferon activity interferon activity being equal to 30-55 MU/ml, favorable disease outcome is considered to be predicted and chemotherapy and interferon are to be administered. General serum interferon activity being greater than 35 MU /ml, α/β interferon activity being less than 60 MU, gamma- interferon activity interferon activity being less than 30 MU, severe development of the disease is predicted as one requiring urgent therapeutic intervention. General serum interferon activity being equal to 12-25 MU /ml, α/β interferon activity equal to than 85-250 MU, gamma- interferon activity interferon activity being equal to 45-110 MU, pathological process eronization is predicted and interferon preparations are administered. General serum interferon activity being equal to 0-10 MU /ml, α/β interferon activity being less than 40 MU, gamma- interferon activity interferon activity being less than 20 MU, unfavorable outcome is predicted. General serum interferon activity being equal to 12-40 MU /ml, α/β interferon activity being equal to 60-400 MU, gamma- interferon activity interferon activity being greater than 250 MU, neuroimmune pathology is predicted to develop. EFFECT: simplified method. 3 cl, 1 dwg, 1 tbl